logo-loader
RNS
viewGlaxoSmithKline PLC

GlaxoSmithKline PLC - Director/PDMR Shareholding

RNS Number : 3930X
GlaxoSmithKline PLC
18 December 2019
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

b)

Nature of the transaction

Transfer of 49,453 Ordinary Shares between accounts for nil consideration.

 

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.00

49,453






d)

Aggregated information

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2019-12-17

f)

Place of the transaction

 

N/A



 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

b)

Nature of the transaction

Transfer of 49,453 Ordinary Shares to spouse for nil consideration.

 

 

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.00

49,453






d)

Aggregated information

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2019-12-17

f)

Place of the transaction

 

N/A



 

 

 


Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms K Thomson

b)

Position/status

PCA of Mr P Thomson (President, Global Affairs)

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

b)

Nature of the transaction

Receipt of 49,453 Ordinary Shares from spouse for nil consideration.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.00

49,453






d)

Aggregated information

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2019-12-17

f)

Place of the transaction

 

N/A

 

 

 

 

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHDVLFFKLFFFBB

Quick facts: GlaxoSmithKline PLC

Price: 1477.4

Market: LSE
Market Cap: £74.16 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE